Obermatt
See Similar Stocks →

Candel Therapeutics

NMQ:CADL · US1374041093
BiotechnologySmall

360

52
Medium confidence — indicative
Profit price82
Cash yield1
Sales & asset price20
Return on Capital46
Cash Return on Capital61
Return on Equity42
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth77
Long-Term EPS Growth91
Reinvestment62
Price momentum49
Debt load21
Refinancing69
Debt Payback1
Liquidity63
Analyst ratings62
Opinion Changes50
Price Target Upside60
Market mood75
Value Creation5/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Candel Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2003
Employees71
Websitecandeltx.com
ISINUS1374041093
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyOncologyBiotechnologyGeneticsHealth CareHealth DiagnosticsMedicalTherapeutics

Description

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company’s enginee…

Analysis

Middle-of-the-road

Candel Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 5/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Similar Stocks

The companies this stock is ranked against.

Compare Candel Therapeutics with its peers
Replimune Group
NSQ:REPL
1
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zentalis Pharmaceuticals
NMQ:ZNTL
12
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Recursion Pharmaceuticals
NSQ:RXRX
20
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Actuate Therapeutics
NMQ:ACTU
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Tyra Biosciences
NSQ:TYRA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Palvella Therapeutics
NAQ:PVLA
100
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →